BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 25, 2007
 |  BioCentury  |  Product Development

Aiming AAV at PD

Two companies developing gene therapies to treat Parkinson's disease reported news last week, as the gene therapy space continued to show renewed glimmers of life (see Ebb & Flow, A17).

Ceregene Inc. (San Diego, Calif.) announced a worldwide development deal with Genzyme Corp. for its CERE-120 gene therapy program. GENZ (Cambridge, Mass.) will pay $25 million up front and up to $125 million in milestones, plus royalties. In addition, GENZ will pay for 50% of all Phase III trials worldwide (see B3).

Separately, Phase I data were published in The Lancet on a treatment being developed by Neurologix Inc. (NRGX, Fort Lee, N.J.).

Ceregene's therapy uses an adeno-associated viral (AAV) Type 2 vector encoding the neurturin (NTN) gene. NTN is a naturally occurring structural and functional analog of glial cell line-derived neurotrophic factor (GDNF), a protein that has been shown to rescue injured neurons in various toxin models.

NRGX's NLX-P101 also uses AAV to deliver the glutamic acid decarboxylase (GAD) 65 and 67 genes. It is designed...

Read the full 858 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >